You just read:

ARMO BioSciences' AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers

News provided by

ARMO BioSciences, Inc.

06 Jun, 2016, 11:26 ET